HomeCategory

Uncategorized

Partnership Supports National Expansion Objectives as Outpatient Demand for Vascular Care Continues to Grow Tampa, Fla and Greenwich, CT, November 29, 2022 – Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm focused exclusively on the healthcare sector, today announced that it has acquired United Vein & Vascular Centers (“UVVC” or the “Company”),...

Astorg Completes Acquisition of OPEN Health From Amulet Capital Partners, L.P.

LUXEMBOURG & GREENWICH, Conn. & LONDON–(BUSINESS WIRE)–Astorg and Amulet Capital Partners (“Amulet”) today announced that they have completed the previously announced transaction whereby Astorg has acquired OPEN Health, a leading global provider of scientific communications and market access services to the pharmaceutical industry. Established in 2011 and with more than 1,000 employees in 15 locations...

Astorg to acquire global medical communications and market access platform OPEN Health from Amulet Capital Partners

OPEN Health is one of the leading global providers of scientific communications and market access services helping pharmaceutical companies to unlock the full potential of their clinical and commercial assets. Astorg will actively support and accelerate OPEN Health’s next phase of growth and innovation, drawing on their extensive experience of investing in the healthcare space....

GREENWICH, Conn. — (BUSINESS WIRE) — Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, announced today that it has recapitalized Lighthouse Behavioral Health Solutions (“Lighthouse”), a leading network of outpatient substance abuse and mental health treatment facilities headquartered in Columbus, Ohio. Terms...

Amulet will partner with management to build on Remedy’s strong foundation, driving growth organically and through strategic acquisitions Acquisition of the leading health care information platform is the third investment in recently closed Amulet Capital Partners Fund II Greenwich, CT – September 27, 2021 — Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm...

Strong demand from new and existing investors pushes fund well above initial target September 14, 2021 08:00 AM Eastern Daylight Time   GREENWICH, Conn.–(BUSINESS WIRE)–Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, announced today the closing of its second fund, Amulet Capital...

Transaction facilitates the Expansion of Company’s Clinical and Drug Safety Offerings The partnership will secure a team of Pharmacovigilance and Clinical Research experts to support clients, expanding the company’s functional breadth. June 29, 2021 09:00 AM Eastern Daylight Time   PARSIPPANY, N.J. & BOSTON–(BUSINESS WIRE)–SSI Strategy, LLC (“SSI” or the “Company”), a leading Life Sciences...

Greenwich, CT – January 12, 2021 – Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm focused exclusively on the healthcare sector, today announced the promotions of three professionals, effective January 1, 2021. Ramsey Frank, Partner and Co-Founder of Amulet said, “We are delighted to announce these well-deserved promotions for Avi, Carl and...

Funding will fuel expansion across adjacent Life Sciences functions and help create a business accelerator for emerging cell and gene therapy and rare disease companies. PARSIPPANY, NJ and GREENWICH, CT, December 21, 2020 – SSI Strategy Holdings LLC (“SSI Strategy” or the “Company”), a leading Life Sciences consultancy, announced today that it has received a...

Greenwich, CT – December 10, 2020 — Amulet Capital Partners, LP (“Amulet”), a middle-market private equity investment firm based in Greenwich, CT, focused exclusively on the healthcare sector, has closed the previously announced sale of its portfolio company, Synteract (the “Company”), a leading full-service CRO focused on the rapidly growing emerging biopharma segment across all...

Close